CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2019; 40(02): 244-248
DOI: 10.4103/ijmpo.ijmpo_50_18
Original Article

Role of Novel Marker Discovered on Gastrointestinal Stromal Tumor 1 in Evaluation of Gastrointestinal Stromal Tumors

Farhat Abbas
Departments of Pathology, Sher-i-Kashmir Institute of Medical Sciences, Srinagar, Jammu and Kashmir
,
Syed Besina
Departments of Pathology, Sher-i-Kashmir Institute of Medical Sciences, Srinagar, Jammu and Kashmir
,
Summyia Farooq
Department of Pathology, JLNM Hospital Rainawari, Srinagar, Jammu and Kashmir
,
Gull Mohammad Bhat
Departments of Medical Oncology, Sher-i-Kashmir Institute of Medical Sciences, Srinagar, Jammu and Kashmir
,
Shaziya Ashraf
Departments of Pathology, Sher-i-Kashmir Institute of Medical Sciences, Srinagar, Jammu and Kashmir
,
Muzamil Latief
Division of Nephrology, GMC, Secunderabad, Telangana, India
› Author Affiliations
Financial support and sponsorship Nil.

Abstract

Background: Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors arising from myenteric ganglion cells, termed interstitial cells of Cajal. GISTs occur predominantly between 40 and 60 years of age. CD34 was the initially used for diagnosing GIST. Due to its low specificity for GISTs, CD34 was replaced by C-KIT, which is a reliable marker. However, 5% GISTs lack C-KIT expression. Recent studies have shown GIST1 (DOG1) to be a more sensitive and specific marker compared to C-KIT and CD34. Aims and Objectives: The aim was to study histomorphology characteristics and risk stratification of all cases previously diagnosed as GISTs, to evaluate these cases for CD117 and DOG1 expression by immunohistochemistry (IHC) and to see whether there was any advantage in using novel markers (i.e. DOG1) as compared to conventional (C-KIT) in GIST at our center. Materials and Methods: Fifty patients with histomorphologic or imaging impression of GIST were subjected to IHC using C-KIT and DOG1. Results and Conclusion: Of 50 cases 47 (94%) were positive for C-KIT, and all 50 (100%) cases were positive for DOG1. Hence, DOG1 was positive even in C-KIT-negative cases. Therefore, our study suggests that DOG1 should be added to workup of suspected cases of GIST along with C-KIT.



Publication History

Article published online:
03 June 2021

© 2019. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 
  • References

  • 1 Miettinen M, Lasota J. Gastrointestinal stromal tumors (GISTs): Definition, occurrence, pathology, differential diagnosis and molecular genetics. Pol J Pathol 2003; 54: 3-24
  • 2 Rebey HS, Aiad HA. Immunohistochemical expression of DOG 1as a diagnostic marker for gastrointestinal stromal tumors in comparison to C-kit. J Am Sci 2014; 10: 198-205
  • 3 Gina AN, Hala NH, Mohammed FD, Deea F, Ahmed AS. Immunohistochemical study of DOG 1 protein expression in gastrointestinal stromal tumors. Acad J Cancer Res 2012; 5: 61-70
  • 4 Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ. et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347: 472-80
  • 5 Dematteo RP, Heinrich MC, El-Rifai WM, Demetri G. Clinical management of gastrointestinal stromal tumors: Before and after STI-571. Hum Pathol 2002; 33: 466-77
  • 6 Lasota J, Corless CL, Heinrich MC, Debiec-Rychter M, Sciot R, Wardelmann E. et al. Clinicopathologic profile of gastrointestinal stromal tumors (GISTs) with primary KIT exon 13 or exon 17 mutations: A multicenter study on 54 cases. Mod Pathol 2008; 21: 476-84
  • 7 Longley BJ, Reguera MJ, Ma Y. Classes of c-KIT activating mutations: Proposed mechanisms of action and implications for disease classification and therapy. Leuk Res 2001; 25: 571-6
  • 8 Corless CL, Schroeder A, Griffith D, Town A, McGreevey L, Harrell P. et al. PDGFRA mutations in gastrointestinal stromal tumors: Frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol 2005; 23: 5357-64
  • 9 Lasota J, Stachura J, Miettinen M. GISTs with PDGFRA exon 14 mutations represent subset of clinically favorable gastric tumors with epithelioid morphology. Lab Invest 2006; 86: 94-100
  • 10 Sarlomo-Rikala M, Kovatich AJ, Barusevicius A, Miettinen M. CD117: A sensitive marker for gastrointestinal stromal tumors that is more specific than CD34. Mod Pathol 1998; 11: 728-34
  • 11 Simon S, Grabellus F, Ferrera L, Galietta L, Schwindenhammer B, Mühlenberg T. et al. DOG1 regulates growth and IGFBP5 in gastrointestinal stromal tumors. Cancer Res 2013; 73: 3661-70
  • 12 Ríos-Moreno MJ, Jaramillo S, Pereira Gallardo S, Vallejo A, Mora M, García-Escudero A. et al. Gastrointestinal stromal tumors (GISTs): CD117, DOG-1 and PKCθ expression. Is there any advantage in using several markers? Pathol Res Pract 2012; 208: 74-81
  • 13 Katiae V, Hattori T, Micev M, Nagorni A, Ivkoviae V, Gligorijeviae J. et al. Microscopic features and immunohistologic characterization of gastrointestinal stromal tumors. Arch Oncol 2004; 12: 49-50
  • 14 Foo WC, Liegl-Atzwanger B, Lazar AJ. Pathology of gastrointestinal stromal tumors. Clin Med Insights Pathol 2012; 5: 23-33
  • 15 Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ. et al. Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol 2002; 33: 459-65
  • 16 Espinosa I, Lee CH, Kim MK, Rouse BT, Subramanian S, Montgomery K. et al. A novel monoclonal antibody against DOG1 is a sensitive and specific marker for gastrointestinal stromal tumors. Am J Surg Pathol 2008; 32: 210-8
  • 17 Lakshmi VA, Chacko RT, Kurian S. Gastrointestinal stromal tumors: A 7-year experience from a tertiary care hospital. Indian J Pathol Microbiol 2010; 53: 628-33
  • 18 Vij M, Agrawal V, Kumar A, Pandey R. Cytomorphology of gastrointestinal stromal tumors and extra-gastrointestinal stromal tumors: A comprehensive morphologic study. J Cytol 2013; 30: 8-12
  • 19 Liegl B, Hornick JL, Corless CL, Fletcher CD. Monoclonal antibody DOG1.1 shows higher sensitivity than KIT in the diagnosis of gastrointestinal stromal tumors, including unusual subtypes. Am J Surg Pathol 2009; 33: 437-46
  • 20 Kim HC, Lee JM, Kim SH, Kim KW, Lee M, Kim YJ. et al. Primary gastrointestinal stromal tumors in the omentum and mesentery: CT findings and pathologic correlations. AJR Am J Roentgenol 2004; 182: 1463-7
  • 21 Gluszek S, Karcz W, Matykiewicz J, Kot M, Urbaniak A. Gastrointestinal stromal tumors. Gastroenterologia polska 2004; 11: 17-21
  • 22 Reith JD, Goldblum JR, Lyles RH, Weiss SW. Extragastrointestinal (soft tissue) stromal tumors: An analysis of 48 cases with emphasis on histologic predictors of outcome. Mod Pathol 2000; 13: 577-85
  • 23 Fülöp E, Marcu S, Borda A, Moldovan C, Fülöp EF, Loghin A. et al. Histopathological and immunohistochemical features of gastrointestinal stromal tumors. Rom J Morphol Embryol 2011; 52: 555-62
  • 24 Al Hussaini HF. GIST in Saudi Arabia: Multicentric histopathological genetic study of 75 surgically excised cases. Gulf J Oncolog 2012; 11: 31-7
  • 25 Sui XL, Wang H, Sun XW. Expression of DOG1, CD117 and PDGFRA in gastrointestinal stromal tumors and correlations with clinicopathology. Asian Pac J Cancer Prev 2012; 13: 1389-93
  • 26 Miettinen M, Virolainen M, Sarlomo-Rikala Maarit. Gastrointestinal stromal tumors – Value of CD34 antigen in their identification and separation from true leiomyomas and schwannomas. Am J Surg Pathol 1995; 19: 207-16
  • 27 Rebey HS, Abdel-Samie AH. Immunohistochemical expression of DOG1 as a diagnostic marker for gastrointestinal stromal tumors in comparison to c-KIT. J Am Sci 2014; 10: 198-205
  • 28 Blay JJ, Bonvalot S, Casali P. GIST consensus meeting panellists: Consensus meeting for management of gastrointestinal stromal tumors. Report of GIST consensus conference of 20-21 March 2004, under the hospices of ESMO. Ann Oncol 2005; 16: 566-78
  • 29 Loong HH. Gastro-intestinal stromal tumours: A review of current management options. Hong Kong Med J 2007; 13: 61-5
  • 30 Lillemoe KD, Efron DT. Gastointestinaltumors. In: Current Surgical Therapy. USA: Mosby Inc.; 2001: 112-7
  • 31 Boni L, Benevento A, Dionigi G, Rovera F, Dionigi R. Surgical resection for gastrointestinal stromal tumors (GIST): Experience on 25 patients. World J Surg Oncol 2005; 3: 78
  • 32 Geramizadeh B, Jowkar Z, Ranjbar Z. Frequency of KIT mutation in gastrointestinal stromal tumors according to histologic and immunohistochemical findings, the first report from Iran. Iran J Med Sci 2015; 40: 316-21
  • 33 Fatima N, Cohen C, Siddiqui MT. DOG1 utility in diagnosing gastrointestinal stromal tumors on fine-needle aspiration. Cancer Cytopathol 2011; 119: 202-8